- Home
- CTRA vs GMAB Comparison
CTRA vs GMAB Comparison
Compare CTRA & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTRA
- GMAB
- Stock Information
- Founded
- CTRA 1989
- GMAB 1999
- Country
- CTRA United States
- GMAB Denmark
- Employees
- CTRA N/A
- GMAB N/A
- Industry
- CTRA Oil & Gas Production
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- CTRA Energy
- GMAB Health Care
- Exchange
- CTRA Nasdaq
- GMAB Nasdaq
- Market Cap
- CTRA 18.0B
- GMAB 17.4B
- IPO Year
- CTRA 1990
- GMAB N/A
- Fundamental
- Price
- CTRA $23.66
- GMAB $28.61
- Analyst Decision
- CTRA Buy
- GMAB Strong Buy
- Analyst Count
- CTRA 18
- GMAB 7
- Target Price
- CTRA $32.44
- GMAB $41.17
- AVG Volume (30 Days)
- CTRA 10.3M
- GMAB 2.6M
- Earning Date
- CTRA 11-03-2025
- GMAB 11-06-2025
- Dividend Yield
- CTRA 3.72%
- GMAB N/A
- EPS Growth
- CTRA 21.39
- GMAB 77.72
- EPS
- CTRA 2.10
- GMAB 21.62
- Revenue
- CTRA $6,232,000,000.00
- GMAB $3,646,881,232.00
- Revenue This Year
- CTRA $48.46
- GMAB $24.25
- Revenue Next Year
- CTRA $7.60
- GMAB $16.29
- P/E Ratio
- CTRA $11.27
- GMAB $12.75
- Revenue Growth
- CTRA 16.27
- GMAB 32.97
- 52 Week Low
- CTRA $22.33
- GMAB $17.24
- 52 Week High
- CTRA $29.95
- GMAB $33.65
- Technical
- Relative Strength Index (RSI)
- CTRA 52.23
- GMAB 38.05
- Support Level
- CTRA $23.19
- GMAB $29.57
- Resistance Level
- CTRA $23.91
- GMAB $29.30
- Average True Range (ATR)
- CTRA 0.49
- GMAB 0.67
- MACD
- CTRA 0.05
- GMAB -0.56
- Stochastic Oscillator
- CTRA 84.11
- GMAB 5.44
About CTRA Coterra Energy Inc.
Coterra Energy Inc is an independent oil and gas company engaged in the development, exploration, and production of oil, natural gas, and natural gas liquids (NGLs). Its operations are mainly concentrated in areas with hydrocarbon resources, which are conducive to multi-well, repeatable development programs, and include the Permian Basin located in Texas and New Mexico, the Marcellus Shale in northeast Pennsylvania, and the Anadarko Basin located in the mid-continent region in Oklahoma. The company operates in one segment, oil and natural gas development, exploration, and production, in the continental U.S.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.